Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, bolstering the company's expertise in biotechnology, drug delivery, and central nervous system clinical development. The additions come as the company advances its pipeline of novel serotonergic agonists (NSAs) targeting major depressive disorder and generalized anxiety disorder, addressing significant unmet needs in mental health.
Dr. Robert Langer, a renowned figure in biotechnology and drug delivery, is one of the most cited researchers in history. His work has been foundational in the development of controlled-release drug delivery systems and tissue engineering. Dr. Stephen Brannan brings extensive experience in CNS clinical development, having previously led programs at major pharmaceutical companies. Their guidance is expected to accelerate Helus Pharma's disciplined, evidence-based drug development approach.
Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company also has an extensive research portfolio of investigational NSAs.
Helus Pharma's proprietary NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, offering durable improvements in mental health. The company aims to improve the treatment landscape for people suffering from depression, anxiety, and other mental health conditions, which remain largely undertreated despite available therapies.
The appointments signal a strategic move to strengthen the scientific leadership as the company progresses through critical clinical milestones. For business and technology leaders, this underscores the growing convergence of advanced biotechnology and mental health therapeutics, with potential implications for the pharmaceutical industry's shift toward precision medicine and neuroplasticity-based treatments. The addition of high-profile advisors like Dr. Langer may also enhance investor confidence and attract further partnerships.
For more information on Helus Pharma, visit the company's newsroom at https://ibn.fm/HELP or the company's website at www.helus.com.
